(Total Views: 515)
Posted On: 02/15/2021 7:32:51 PM
Post# of 145882
Calstang,
You are correct.
The discussion between Closetinvsetor and JLang today addresses this.
With an expected limited supply of leronlimab, reserving its use for severe/critical Covid seems the appropriate approach over the short term.
The Patterson assay, to identify critically dysregulated patients, in advance of clinical decompensation, seems like a great solution while Cytodyn arranged for the tens of millions of doses needed eventually.
You are correct.
The discussion between Closetinvsetor and JLang today addresses this.
With an expected limited supply of leronlimab, reserving its use for severe/critical Covid seems the appropriate approach over the short term.
The Patterson assay, to identify critically dysregulated patients, in advance of clinical decompensation, seems like a great solution while Cytodyn arranged for the tens of millions of doses needed eventually.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)